The use of psychotropic drugs in the pediatric population has increased significantly in recent years [1•]. Reports of sudden, unexpected death in patients taking these drugs have raised the possibility of ventricular dysrhythmias as the cause of these deaths. Attention has centered on the electrocardiographic effects of psychotropic drugs. In addition, their interaction with other drugs metabolized by the cytochrome P450 (CYP450) system has come under scrutiny. Many psychotropic drugs affect electrolyte currents through ion channels. Myocardial repolarization is a function of ionic currents through these same channels. Alterations in sodium and potassium currents may prolong repolarization and increase the vulnerability of the myocardium to sudden ventricular dysrhythmias, particularly torsades de pointes. Effects on the electrocardiogram may be primarily significant or may be significant only in the presence of inherited or acquired predisposing factors. The Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young of the American Heart Association has published a statement for healthcare professionals concerning cardiovascular monitoring of children and adolescents receiving psychotropic drugs [2••]. It is important to understand the relation between the susceptibility of the heart to dysrhythmias and the use of psychotropic drugs. This article reviews various factors that may affect the electrocardiogram, the effects of specific psychotropic drugs on the electrocardiogram, and recommendations for electrocardiogram monitoring for patients on these drugs.
Factors that may increase susceptibility in patients taking psychotropic drugs Genetic predisposition
Certain inherited congenital abnormalities of cardiac ionic channel function can lead to prolonged repolarization of the myocardium and can increase the risk of sudden dysrhythmias. This effect appears as a prolonged QTc interval on the electrocardiogram. The QTc is the measured QT interval corrected for heart rate. These inherited conditions include Romano-Ward syndrome (autosomal dominant) and Lange-Jervell-Nielsen syndrome (autosomal recessive with congenital hearing loss). Bradycardia, fright, loud noises, and exercise may provide settings particularly dangerous for patients with these syndromes. Other risk factors include serum electrolyte abnormalities; female gender; and renal, liver, or structural cardiac disease. Before instituting therapy with psychotropic drugs that may further prolong the QTc interval, a detailed history should be obtained from the patient and family to document any history of palpitations, syncope, or near-syncope. A detailed family history should also be obtained. This family history should include inquiring about known relatives with prolonged QTc syndrome or the presence of sudden unexpected cardiac death, seizures, or syncope, especially in settings that may suggest an inherited prolonged QTc syndrome. Pharmacogenetics is an area of increasing interest, especially research concerning the existence of inheritable abnormalities of drug metabolism, which may predispose subpopulations to higher levels and effects of drugs metabolized by the CYP450 system. As much as 10% of the population may have impaired function of one or more of the isoenzymes of the CYP450 system. These poor metabolizers may have increased risk for proarrhythmia and sudden cardiac death [3••]. As identification of altered metabolism becomes clinically available, it may be possible to identify populations that are at increased risk. Until pharmacogenetic predisposition to drug effects is more fully elaborated, an accurate, detailed history and a screening baseline electrocardiogram are the only tools to evaluate for genetic susceptibility to drug effects and sudden cardiac death.
Structural cardiac disease
Underlying structural cardiac disease can predispose to heterogeneous ventricular depolarization and repolarization. Premature ventricular contractions are more common in patients with pre-existing heart disease. Preexisting heart disease increases the risk of ventricular dysrhythmias, which may trigger torsades de pointes in prolonged repolarization. Caution should be exercised when considering the use of psychotropic drugs that prolong the QTc interval or cause torsades de pointes in patients who have underlying structural heart disease.
Metabolism and clearance of psychotropic drugs and drug-drug interactions
Over 90% of drug oxidation and metabolism can be attributed to the cytochrome P450 enzyme system. Five isoenzymes are responsible for most of this metabolism: 3A4, 2D6, 1A2, 2C9, and 2C19. The 3A4 isoenzyme is involved in the widest range of drug metabolism, including liver and gut. Drugs that are substrates for a particular isoenzyme may competitively inhibit metabolism. Other drugs may directly inhibit isoenzyme function. Either of these effects may cause an increase in serum concentrations of psychotropic drugs with resultant risk of prolongation of the QTc interval and torsades de pointes. Clinically significant drug-drug interactions exist. Many psychotropic drugs are metabolized through the CYP450 system. If the function of this enzyme system is inhibited directly or indirectly, elevated levels of drugs that effect cardiac repolarization may occur, with the potential for serious ventricular dysrhythmias. This is especially true of drugs primarily metabolized via the 3A4 isoenzyme of CYP450 [4] . Patients and families should be counseled about these possible interactions. Before starting new or additional medications, the physician or pharmacist should be queried concerning possible interactions with psychotropic drugs. This is especially true for drugs that are metabolized via CYP450 isoenzyme 3A4, such as macrolide antibiotics, and systemic antifungal medications. There are many cardiac medications that cause prolongation of the QTc interval, both as a specific therapeutic effect and as a side effect. Before adding any cardiac medication in a patient also taking psychotropic medications, specific attention to the potential for drug-drug interactions and QTc prolongation must be addressed.
Health care professionals should be cognizant of drug interactions that may alter drug metabolism and clearance. It is also imperative to warn patients and families about the potentially lethal consequences of using multiple drugs metabolized by the CYP450 system. Additions of new drugs, changes in clinical status, and changes in drug dosage should be considered in the decision about the use of psychotropic drugs and electrocardiographic monitoring (Tables 1 and 2 ).
Acute and chronic overdose
There are reports of electrocardiogram effects from psychotropic drugs in both acute and chronic overdose. Some drugs prolong the QTc interval in the therapeutic range but have not been reported to cause torsades de pointes in the literature or US Food and Drug Administration labeling. However, these drugs may cause clinically significant QTc prolongation in overdose. Clinicians should be aware of the possibility of significant electrocardiogram abnormalities and risk of dysrhythmias that may result from acute or chronic overdose of drugs that affect the QTc interval. Even drugs not recom-mended for routine electrocardiogram monitoring in therapeutic usage might have serious toxic effects in overdose. In acute or chronic overdose, electrocardiogram monitoring is essential. The clinician should also be aware that coingestion of other drugs in overdose that are metabolized by the CYP450 system might transform therapeutic levels of psychotropic drugs into toxic levels [4, 5] .
Specific psychotropic medications and recommendations for monitoring Stimulants
Stimulants are the leading category of psychotropic medication prescribed for children (Table 3) . Methylphenidate (Ritalin; Novartis Pharmaceutical Corp., East Hanover, NJ) is the most commonly prescribed medication for attention-deficit hyperactivity disorder. In addition, sustained-release methylphenidate (Concerta), pemoline (Cylert; Abbott Laboratories, Abbott Park, IL), and dextroamphetamine (Adderall; Richwood Pharmaceuticals, Florence, KY) are used. Underlying cardiac disorders such as supraventricular or ventricular tachydysrhythmias may be unmasked by stimulant medications. No specific electrocardiogram monitoring is recommended for stimulant monotherapy. There have been isolated reports of sudden death in children taking both methylphenidate and clonidine together. Although the exact mechanism remains unclear, it seems unlikely that these were dysrhythmic deaths [6, 7] . No specific electrocardiogram monitoring is recommended [2••].
Antidepressants

Tricyclic antidepressants
Tricyclic antidepressants have been largely replaced by newer antidepressants, but they are still used in the treatment of depression and attention-deficit hyperactivity disorder. In addition, nocturnal enuresis and chronic pain are conditions for which tricyclic antidepressants are used. Several sudden deaths in children taking tricyclic antidepressants have been reported [8] . Nortriptyline, amitriptyline, desipramine, and imipramine may have significant cardiac effects with prolongation of the PR, QRS, and QTc intervals, even in therapeutic doses [9] . Significant drug-drug interactions exist. For example, methylphenidate may decrease metabolism, which may increase the concentration of tricyclic antidepressants. Synergism with other sympathomimetic drugs also occurs. The current recommendations include a careful history with a family history to screen for familial pro- depressants. Fluoxetine has been reported to prolong the QTc interval, which causes syncope [10] . Citalopram has been reported to show no significant effects on cardiac intervals in therapeutic usage but may prolong the QTc in overdose [11] . Paroxetine has been shown to lengthen the QTc interval, and the Food and Drug Administration labeling mentions torsades de pointes [12] . The different selective serotonin reuptake inhibitors are metabolized by different cytochrome P450 enzymes, and potential interactions with other drugs that share the same metabolism should be monitored [13•]. Although no consensus has been established, baseline electrocardiogram measurements may be considered before instituting selective serotonin reuptake inhibitor therapy. Baseline 1A2  cimetidine  fluoroquinolones  fluvoxamine  ticlodipine  2C19  fluoxetine  lansoprazole  fluvoxamine  omeprazole  ketoconazole  ticlodipine  2C9  amiodarone  ticlodipine  fluconazole  isoniazid  2D6  amiodarone  chloripramine  methadone  quinidine  bupropion  fluoxetine  mibefradil  ritonavir  chlorpheniramine  haloperidol  paroxetine  cimetidine  2E1  disulfram  3A4  indinavir  amiodarone  fluoxetine  ketoconazole  nelfinavir  cimetidine  fluvoxamine  mibefradil  ritonavir  clarithromycin  grapefruit juice  nefazodone  saquinavir erythromycin itraconazole troleandomy *Simultaneous use of drugs that are substrates for the CTP 450 system may lead to competitive inhibition and altered levels of drugs and active metabolites. ECG monitoring is recommended when these drugs are used in combination with drugs known to prolong the QTc. †
The simultaneous use of drugs that alter cytochrome P 450 function may alter drug and active metabolite levels. ECG monitoring is recommended when these drugs are used in combination with drugs known to prolong the QTc.
electrocardiogram measurements should include a PR interval Յ 200 ms, a QRS duration Յ 120 ms, and a QTc Յ 460 ms. Electrocardiogram monitoring is indicated in proven or suspected overdose.
Newer antidepressants
Bupropion (Wellbutrin; GlaxoWellcome, Research Triangle Park, NC) increases dopamine reuptake and has minor effects on norepinephrine reuptake. Bupropion is metabolized by the 2B6 isoenzyme of the CYP450 system and can inhibit the 2D6 isoenzyme. No change in the QTc has been reported with bupropion, but caution should be exercised when using other drugs metabolized by the CYP450 system. Venlafaxine (Effexor; WyethAyerst Laboratories, Philadelphia, PA) inhibits the reuptake of serotonin and norepinephrine. At high doses, it also inhibits the reuptake of dopamine. Venlafaxine has been shown to cause prolongation of the QTc interval in overdose but not at therapeutic levels. 
Conclusions
Psychotropic drugs are used in a wide variety of clinical settings. Ventricular dysrhythmias are an unusual but potentially life-threatening side effect of these drugs. Multiple factors affect concentration of psychotropic drugs and vulnerability to dysrhythmias. These factors include dosage, genetic predisposition, drug-drug interactions, clearance, and metabolism. It is imperative that patients, families, and health care professionals understand these potentially lethal interactions. Brief communication concerning the future of pharmacogenetics and the possibility of genetic screening for drug susceptibility in the future. Raises very interesting issues.
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